Streetbeat News

KRRO

Korro Bio, Inc.

https://www.korrobio.com

Industry

Biotechnology

Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.

Open

28.27

Mkt cap

231M

Volume

110K

High

28.49

P/E Ratio

-2.61

52-wk high

98.00

Low

23.69

Div yield

N/A

52-wk low

18.50

Korro Bio, Inc. has received orphan drug designation from the FDA for its investigational medicine KRRO-110, aimed at treating Alpha-1 Antitrypsin Deficiency.

Portfolio Pulse from

March 14, 2025 | 12:15 pm

Korro Bio, Inc. (Nasdaq: KRRO), a clinical-stage biopharmaceutical company, will participate in upcoming investor conferences. The company focuses on developing genetic medicines based on RNA editing for various diseases.

Portfolio Pulse from

November 21, 2024 | 9:15 pm

Korro has received Australian HREC approval and CTN clearance to begin a Phase 1/2a clinical study of KRRO-110 for Alpha-1 Antitrypsin Deficiency. The study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of KRRO-110.

Portfolio Pulse from

November 21, 2024 | 12:45 pm

Korro Bio, Inc. (Nasdaq: KRRO) will present at the Jefferies London Healthcare Conference on November 19, 2024. The presentation will be led by CEO Ram Aiyar, with participation from CFO Vineet Agarwal and CMO Kemi Olugemo.

Portfolio Pulse from

November 14, 2024 | 1:15 pm

RBC Capital analyst Luca Issi has maintained an 'Outperform' rating on Korro Bio (NASDAQ:KRRO) and raised the price target from $95 to $105.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 1:31 pm

Raymond James has initiated coverage on Korro Bio with a Strong Buy rating and set a price target of $153.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 1:22 pm

HC Wainwright & Co. has maintained a Buy rating on Korro Bio and increased the price target from $100 to $115, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 11:00 am

The article highlights significant intraday movements in healthcare stocks, with notable gainers including 180 Life Sciences, Korro Bio, and Universe Pharmaceuticals, and losers such as Novavax and Tevogen Bio Holdings.

Portfolio Pulse from Benzinga Insights

October 16, 2024 | 4:31 pm

United Airlines reported better-than-expected earnings, leading to a 9.3% stock increase. Other stocks like Korro Bio, Wave Life Sciences, and Morgan Stanley also saw significant gains due to positive developments.

Portfolio Pulse from Avi Kapoor

October 16, 2024 | 2:23 pm

RBC Capital analyst Luca Issi has reiterated an Outperform rating on Korro Bio (NASDAQ:KRRO) and maintained a price target of $95.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 2:09 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.